Cómo funciona la asistencia
Optimizando la experiencia de farmacia especializada de nuestros pacientes con una comodidad de servicio completo sin igual
-
1. Verifique su cobertura/verificación de beneficios
Nuestro equipo de facturadores expertos encuentra las mejores vías de cobertura que minimizan los costos de bolsillo.
-
2. Transferir receta a AmeriPharma®
Procesamos su receta trabajando con su farmacia o prescriptor anterior, haciendo que la transición sea rápida y sencilla.
-
3. Autorización previa
Nuestro equipo de especialistas obtiene la aprobación de sus compañías de seguros en un plazo de 24 a 72 horas.
-
4. Asistencia para copagos y ayuda financiera
Garantizamos ayuda financiera y reducimos copagos, gastos de bolsillo y deducibles elevados. Hasta la fecha, AmeriPharma® Specialty Care ha obtenido $55 millones en asistencia financiera para nuestros pacientes.
-
5. Coordinación de atención de enfermería si es necesario
AmeriPharma® prioriza su agenda y su entorno hogareño al programar y coordinar una de nuestras enfermeras especializadas para sus infusiones en el hogar.
-
6. Coordinación de entrega
Los medicamentos se entregan siempre en estricto cumplimiento de los requisitos específicos de envío. Las entregas con cadena de frío al día siguiente y al día siguiente se coordinan según su horario.
What Is Eltrombopag?
Eltrombopag (brand name Promacta) is an oral medication prescribed to increase platelet counts in people with certain blood disorders, including chronic immune thrombocytopenia (ITP). Platelets are blood cell fragments that help form clots and stop bleeding.
In 2008, eltrombopag (Promacta) received approval from the Food and Drug Administration (FDA) to treat certain adults with chronic immune thrombocytopenia (ITP). The FDA later expanded its approved uses to include other conditions associated with low blood cell counts. Common side effects of this drug may include nausea, headache, diarrhea, urinary tract infections, upper respiratory tract infections, and fever.
Eltrombopag (Promacta): FDA-Approved Uses
The FDA has approved eltrombopag (Promacta) for several conditions associated with low platelet or blood cell counts, including persistent or chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older. Its approved uses include:
- To treat adults and children aged 1 year and older with persistent or chronic ITP who have not responded adequately to corticosteroids, inmunoglobulinas, or splenectomy. It should be used only in patients whose condition and degree of thrombocytopenia increase their risk of bleeding.
- To treat low platelet counts in patients with chronic hepatitis C who need to start and maintain interferon-based therapy.
- As first-line treatment in combination with standard immunosuppressive therapy for adults and children aged 2 years and older with severe aplastic anemia (SAA).
- To treat patients with severe aplastic anemia (SAA) who have not responded adequately to immunosuppressive therapy.
Promacta (eltrombopag) is not recommended to treat patients with myelodysplastic syndromes (MDS).
Mecanismo de acción (MOA)
Eltrombopag (Promacta) belongs to the class of medicines called thrombopoietin receptor (TPO) agonists. It activates thrombopoietin receptors in the bone marrow, stimulating the production of platelets.
By increasing platelet production, eltrombopag (Promacta) can help reduce the risk of bleeding in patients with low platelet counts. In patients with severe aplastic anemia, it may also improve red and white blood cell counts.
How Eltrombopag Copay Assistance Works
La farmacia especializada AmeriPharma® alivia las cargas financieras de los pacientes y sus familias.
-
Un software avanzado localiza fuentes de financiación para conectarlo con programas de fundaciones de alto valor
-
Uno de nuestros especialistas en asistencia de copagos le ayudará con el proceso de solicitud.
-
Se le enviarán a usted y a su médico actualizaciones automáticas sobre el estado de la financiación.
Dosis recomendada
The dosage of eltrombopag (Promacta) varies depending on the condition being treated, the patient’s age, liver function, and response to treatment. Below are the recommended dosages for adult and pediatric patients indicated by the FDA.
Dosage for Persistent or Chronic ITP
The recommended starting dose for most adults and children aged 6 years and older with persistent or chronic ITP is 50 mg orally once daily. For children aged 1 to 5 years, the recommended starting dose is 25 mg once daily.
Dosage for Chronic Hepatitis C-associated Thrombocytopenia
For patients with chronic hepatitis C-associated thrombocytopenia, the recommended starting dose of Promacta is 25 mg orally once daily. The dose may be adjusted based on platelet counts and treatment response.
First-line Severe Aplastic Anemia
The dosage of Promacta in combination with standard immunosuppressive therapy for the treatment of severe aplastic anemia is as follows:
- For pediatric patients aged 2 to 5 years: Promacta orally once daily at 2.5 mg/kg
- For pediatric patients aged 6 to 11 years: one 75 mg tablet once a day
- For patients aged 12 years and older: 150 mg orally once daily, concurrently with standard immunosuppressive therapy.
Refractory Severe Aplastic Anemia
The recommended starting dosage for patients with refractory severe aplastic anemia is 50 mg orally once daily. The dose may be adjusted based on blood counts and treatment response.
Patients with liver problems or East- or Southeast-Asian ancestry may require a lower starting dose of Promacta. However, dosage adjustments vary depending on the condition being treated. Your healthcare provider will determine the appropriate dose and adjust it based on your response to treatment.
Eltrombopag Side Effects
Los efectos secundarios comunes incluyen:
- Low levels of red blood cells (anemia)
- Náuseas
- Fiebre
- Abnormal liver function tests
- Tos
- Sentirse cansado
- Dolor de cabeza
- Diarrea
- Erupción
- Skin discoloration (hyperpigmentation)
Los efectos secundarios graves incluyen:
- Reacciones alérgicas graves
- Liver damage (hepatotoxicity)
- High platelet counts and an increased risk of blood clots
- Worsening liver function in patients with chronic hepatitis C who receive Promacta with interferon and ribavirin
- Increased risk of cataracts or worsening progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML)
Seguros aceptados
Aceptamos Medicare, Medicaid multiestatal, Medi-Cal, Blue Shield y la mayoría de los seguros privados. Llámenos para obtener más información sobre su cobertura.
Comience en minutos
Complete sus datos y uno de nuestros especialistas le llamará lo antes posible.
¿Cuánto puedes ahorrar?
Complete este formulario para ahorrar hasta 100%!

Al enviar, acepta los términos y condiciones de AmeriPharma. Condiciones de uso, política de privacidad, y Aviso de prácticas de privacidad